Becton, Dickinson and Company (BDX) Earnings Call Transcripts
Becton, Dickinson and Company's Latest Earnings Call - Q3 FY2026
In the third quarter of fiscal 2026, Becton, Dickinson and Company (BDX) reported revenue of $5 billion, reflecting a 4.4% increase year-over-year, driven by strong performance across key growth platforms. Adjusted EPS came in at $3.23, exceeding expectations and marking a 4.9% increase. Management raised guidance for the full year, now anticipating revenue growth toward the high end of the low single-digit range and increasing the midpoint of adjusted EPS guidance to $12.62 to $12.72.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $5 billion (beat) |
| Adjusted EPS | $3.23 (beat) |
| Adjusted Operating Margin | 24.9% (negative) |
| Free Cash Flow | $1.7 billion (positive) |
| Guidance for Adjusted EPS | $12.62 to $12.72 (positive) |
| Medical Essentials Growth | 3.2% (positive) |
Guidance from management
Management updated full-year guidance, now expecting revenue growth toward the high end of the low single-digit range and raised the midpoint of adjusted EPS guidance to $12.62 to $12.72.
What analysts pressed on
Analysts expressed concerns about the ongoing headwinds from Alaris and the vaccine market in China. There were questions regarding the visibility of these challenges and how they would impact future growth, particularly in fiscal 2027.
Main topics on the call
- Revenue Growth Acceleration — BDX experienced a 4.4% increase in revenue, with over 90% of the portfolio delivering high single-digit growth. Management noted, "Performance continues to be driven by ongoing structural improvements across our key grow...
- Adjusted EPS Performance — The company reported adjusted EPS of $3.23, which was ahead of expectations. This reflects strong revenue performance and operational execution, as highlighted by management's statement, "We delivered a strong third quar...
- Guidance Update — Management raised the midpoint of adjusted EPS guidance for the full year to $12.62 to $12.72, indicating confidence in continued momentum. They stated, "Based on our Q3 performance, strong year-to-date execution and con...
- Commercial Excellence Strategy — BDX is focusing on enhancing commercial execution, with investments leading to share gains and growth in key areas. Polen mentioned, "We're winning more consistently scaling our growth platforms faster and strengthening ...
Read the full Becton, Dickinson and Company transcript (Q3 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Becton, Dickinson and Company
Becton, Dickinson and Company (BDX) is a publicly listed company in the Health Care Equipment and Supplies industry, within the Health Care sector. It trades on NYSE and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 82 calls on record spanning January 14, 2020 to August 6, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 82 Becton, Dickinson and Company earnings call transcripts on record, spanning January 14, 2020 to August 6, 2026. Based on this history, Becton, Dickinson and Company reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- BDX
- Exchange
- NYSE
- Country
- US
- Sector
- Health Care
- Calls on record
- 82
- First call
- January 14, 2020
- Most recent
- August 6, 2026
- Reporting cadence
- quarterly